

**Company registration number: 724454**

**ASKONA SCIENTIFIC LIMITED**  
**Trading as ASKONA SCIENTIFIC LIMITED**  
**Unaudited abridged financial statements**  
**for the financial year ended 31 July 2025**

# ASKONA SCIENTIFIC LIMITED

## Contents

	<b>Page</b>
Directors and other information	<b>1</b>
Directors responsibilities statement	<b>2</b>
Accountants report	<b>3</b>
Balance sheet	<b>4</b>
Notes to the financial statements	<b>5 - 6</b>

## **ASKONA SCIENTIFIC LIMITED**

### **Directors and other information**

<b>Directors</b>	Burak Ozsogut
<b>Secretary</b>	Mr Michael Kelly
<b>Company number</b>	724454
<b>Registered office</b>	ASKONA SCIENTIFIC LIMITED Unit 1, Chesterfield, Clonmannon Ashford WICKLOW A67 WR29
<b>Business address</b>	Unit 1 Chesterfield, Clonmannon Ashford WICKLOW A67 WR29
<b>Accountants</b>	Devaney & Durkin Accountants 1 Ontario Terrace Ranelagh Dublin D06 H2W9
<b>Bankers</b>	HypoVereinsbank

## **ASKONA SCIENTIFIC LIMITED**

### **Directors responsibilities statement**

These abridged financial statements have been extracted, pursuant to section 353 of the Companies Act 2014, from the statutory financial statements prepared under section 290 of that Act. The following is the Directors Responsibilities Statement accompanying those financial statements.

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law, they have elected to prepare the financial statements in accordance with FRS 105 The Financial Reporting Standard applicable to the Micro-entities Regime (FRS 105).

As such the directors are responsible for preparing financial statements in accordance with the provisions of the Companies Act 2014 with which the company is obliged to comply, including the appropriate use of the going concern basis of accounting, which is consistent with those requirements, and having availed of the exemptions to which the company is entitled by virtue of qualifying for the micro companies regime and FRS 105. Thereby, the financial statements are presumed, in law, to give a true and fair view without any consideration of any other circumstances, factors, accounting principles or disclosures.

The directors are responsible for keeping adequate accounting records which disclose with reasonable accuracy at any time the assets, liabilities, financial position and profit or loss of the company and enable them to ensure that the financial statements comply with the Companies Act 2014. They have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the company and to prevent and detect fraud and other irregularities. The directors are also responsible for preparing a directors report that complies with the requirements of the Companies Act 2014.

Burak Ozsogut  
**Director**

**ASKONA SCIENTIFIC LIMITED**

**Accountants' Report to the board of directors  
on the Unaudited abridged financial statements of ASKONA SCIENTIFIC LIMITED**

In accordance with the engagement letter dated , and in order to assist you to fulfil your duties under the Companies Act 2014, we have compiled the financial statements which comprise the profit and loss account, balance sheet and related notes from the accounting records and information and explanations you have given to us.

This report is made to the company's board of directors, as a body, in accordance with the terms of our engagement. Our work has been undertaken so that we might compile the financial statements that we have been engaged to compile, report to the company's board of directors that we have done so, and state those matters that we have agreed to state to them in this report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's board of directors for our work or for this report.

We have carried out this engagement in accordance with guidance issued by the Institute of Chartered Accountants in Ireland and have complied with the ethical guidance laid down by the Institute relating to members undertaking the compilation of financial statements.

You have acknowledged on the balance sheet for the financial year ended 31 July 2025 your duty under the Companies Act 2014 to ensure that the company has kept adequate accounting records and prepared financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for that financial year, and otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company. You consider that the company is exempt from the statutory requirement for an audit for the financial year.

We have not been instructed to carry out an audit of the financial statements. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the financial statements.

Devaney & Durkin Accountants

1 Ontario Terrace  
Ranelagh  
Dublin  
D06 H2W9

31 March 2026

**ASKONA SCIENTIFIC LIMITED**

**Balance sheet  
As at 31 July 2025**

	<b>2025</b>	2024
	<b>€</b>	€
Current assets	9,020	6,248
Creditors: amounts falling due within one year	<u>(28,000)</u>	<u>(20,000)</u>
<b>Net current liabilities</b>	<u>(18,980)</u>	<u>(13,752)</u>
<b>Total assets less current liabilities</b>	(18,980)	(13,752)
Accruals and deferred income	(2,906)	(2,471)
<b>Net liabilities</b>	<u><u>(21,886)</u></u>	<u><u>(16,223)</u></u>
<b>Capital and reserves</b>	<u><u>(21,886)</u></u>	<u><u>(16,223)</u></u>

We, as directors of ASKONA SCIENTIFIC LIMITED state that:

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 of the Companies Act 2014 are satisfied;
- (c) the shareholders of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- (e) the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a micro company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

The financial statements have been prepared in accordance with the micro companies regime.

These abridged financial statements were approved by the board of directors on 31 March 2026 and signed on behalf of the board by:

**Burak Ozsogut**  
Director

## ASKONA SCIENTIFIC LIMITED

### Notes to the abridged financial statements Financial year ended 31 July 2025

#### 1. General information

The company is a private company limited by shares, registered in . The address of the registered office is ASKONA SCIENTIFIC LIMITED, Unit 1,, Chesterfield, Clonmannon, Ashford, WICKLOW, A67 WR29.

#### 2. Statement of compliance

These financial statements have been prepared in accordance with FRS 105, 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

#### 3. Accounting policies and measurement bases

##### Basis of preparation

The financial statements have been prepared on the historical cost basis.

The financial statements are prepared in Euro, which is the functional currency of the entity.

##### Taxation

Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Tax is recognised on taxable profit for the current and past periods. Tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

##### Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Financial instruments are initially recognised at cost, which is the transaction price.

Investments in shares, subsidiaries or participating interests are subsequently measured at cost less impairment.

Derivatives are subsequently measured at the cost plus any transaction costs not immediately recognised in profit or loss less any impairment losses recognised to date. This is allocated to profit or loss over the term of the contract on a straight-line basis, unless another systematic basis of allocation is more appropriate.

Other financial instruments are subsequently measured at the cost plus any transaction costs not immediately recognised in profit or loss, plus accumulated interest income or expense recognised to date, less all repayments of principal or interest to date, less impairment.

Financial assets are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

Any reversals of impairment are recognised in profit or loss immediately.

**ASKONA SCIENTIFIC LIMITED**

**Notes to the abridged financial statements (continued)**  
**Financial year ended 31 July 2025**

<b>4. Appropriations of profit and loss account</b>	<b>2025</b>	2024
	€	€
At the start of the financial year	(16,323)	(6,034)
Loss for the financial year	(5,663)	(10,289)
<b>At the end of the financial year</b>	<u>(21,986)</u>	<u>(16,323)</u>
<b>5. Debtors</b>	<b>2025</b>	2024
	€	€
Other debtors	2,000	2,000
	<u>2,000</u>	<u>2,000</u>
<b>6. Cash and cash equivalents</b>	<b>2025</b>	2024
	€	€
Cash at bank and in hand	7,020	4,248
	<u>7,020</u>	<u>4,248</u>
<b>7. Creditors: amounts falling due within one year</b>	<b>2025</b>	2024
	€	€
Other creditors	28,000	20,000
Accruals	2,906	2,471
	<u>30,906</u>	<u>22,471</u>